目的 探讨小青龙颗粒联合布地奈德气雾剂治疗支气管哮喘急性发作期的临床疗效。方法 选取2016年2月—2018年2月澄迈县人民医院收治的支气管哮喘急性发作期患者132例为研究对象，根据随机数字表法将患者分为对照组和治疗组，每组各66例。对照组患者雾化吸入布地奈德气雾剂，2揿/次，2～4次/d；治疗组在对照组治疗的基础上口服小青龙颗粒，1袋/次，3次/d。两组患者均连续用药7 d。观察两组的临床疗效，比较两组的临床症状消失时间、肺功能指标、血清炎性因子。结果 治疗后，对照组和治疗组的总有效率分别为83.3%、92.4%，两组比较差异有统计学意义（P<0.05）。治疗后，治疗组咳嗽、气喘、湿啰音、哮鸣音消失时间均显著短于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组PEV1、PEF、FVC、PEV1/FVC均显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组肺功能指标明显高于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组血清IL-17、IL-35、HMGB1水平均明显下降，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组血清炎性因子水平明显低于对照组，两组比较差异有统计学意义（P<0.05）。结论 小青龙颗粒联合布地奈德气雾剂治疗支气管哮喘急性发作期具有较好的临床疗效，可缓解临床症状，改善肺功能，降低炎症反应，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Xiaoqinglong Granules combined with Budesonide Inhalation Aerosol in treatment of acute attack of bronchial asthma. Methods Patients (132 cases) with acute attack of bronchial asthma in Chengmai County People's Hospital from February 2016 to February 2018 were randomly divided into control and treatment groups, and each group had 66 cases. Patients in the control group were atomization inhalation administered with Budesonide Inhalation Aerosol, 2 presses/time, 2-4 times daily. Patients in the treatment group were po administered with Xiaoqinglong Granules on the basis of the control group, 1 bag/time, three times daily. Patients in two groups were treated for 2 d. After treatment, the clinical efficacies were evaluated, and the disappearing time of clinical symptoms, lung function indexes, and serum inflammatory factors in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 83.3% and 92.4%, respectively, and there was difference between two groups (P<0.05). After treatment, the disappearing times of cough, asthma, moist rale and wheezing in the treatment group were significantly shorter than those in the control group, and there was difference between two groups (P<0.05). After treatment, PEV1, PEF, FVC, and PEV1/FVC in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the lung function indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of IL-17, IL-35,and HMGB1 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the serum inflammatory factors indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Xiaoqinglong Granules combined with Budesonide Inhalation Aerosol has clinical curative effect in treatment of acute attack of bronchial asthma, can relieve clinical symptoms, improve pulmonary function, and reduce inflammatory response, which has a certain clinical application value.